Pionyr Immunotherapeutics Inc. logo

Pionyr Immunotherapeutics Inc.

Pionyr Immuntherapeutics is developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company’s approach, Myeloid Tuning™, is designed to enhance the immune system’s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.
Pionyr was founded by Profs. Max Krummel of UCSF and Sachdev Sidhu of U.of Toronto discovering and developing immuno-oncology antibody therapeutics.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.pionyrtx.com
Founded2015
Disease Focus
Development Stage
STOCK CODENon Listed
Address
953 Indiana Street, CA, 94107
San Francisco
United States
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/pionyr-immunotherapeutics” connections=”true” suffix=””]

Pionyr is exploiting novel target discovery and antibody generation platform technologies to create the third generation of immuno-oncology therapeutics after checkpoint inhibitors and CAR-T. The companys approach, Myeloid Tuning_, is designed to enhance the immune systems anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.

In Dec 2017, Pionyr raised $62 Mn in a Series B round led by New Enterprise Associates and included Sofinnova Ventures and Vida Ventures, along with Pionyrs existing investors, OrbiMed, SV Health Investors, Osage University Partners, and Mission Bay Ventures.

In Jan 2017, Pionyr raised $8 Mn in a series A-1 round led by OrbiMed and SV Life Sciences. Osage University Partners, Mission Bay Ventures alongwith other private angel investors.